3.89  0.5 (14.75%)		03-09 16:00
Open: 3.4 High: 3.91 Volume: 9,154,411		Pre. Close: 3.39 Low: 3.38 Market Cap: 734(M)

Short term
Mid term
Targets	6-month :	5.13	1-year :	6
Resists	First :	4.4	Second :	5.13
Pivot price	3.82
Supports	First :	3.73	Second :	3.31
MAs	MA(5) :	3.64	MA(20) :	3.81
	MA(100) :	4.25	MA(250) :	3.46
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	20.1	D(3) :	16.9
RSI	RSI(14): 52
52-week	High :	6.75	Low :	1.14

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ATAI ] has closed below upper band by 43.6%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.58 - 3.6	3.6 - 3.62
Low:	3.33 - 3.36	3.36 - 3.38
Close:	3.35 - 3.39	3.39 - 3.42

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

Mon, 09 Mar 2026
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection - TipRanks

Sun, 08 Mar 2026
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Yahoo Finance UK

Fri, 06 Mar 2026
AtaiBeckley releases pro forma financials following Beckley Psytech acquisition - Investing.com Nigeria

Fri, 06 Mar 2026
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com

Fri, 06 Mar 2026
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - Investing News Network

Fri, 06 Mar 2026
AtaiBeckley funds new depression and social anxiety drugs into 2029 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	-39 (M)
Shares Float	0 (M)
Held by Insiders	3.6321e+008 (%)
Held by Institutions	3.013e+008 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	2.53e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.83
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	796.5 %
Return on Equity (ttm)	-29.3 %
Qtrly Rev. Growth	3.02e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.0142e+008 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-4.69
Price to Sales	0
Price to Cash Flow	0

Dividend	1.49e+007
Forward Dividend	1.459e+007
Dividend Yield	383033000%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.